Search
forLearn
5 / 6 resultslearn Tofacitinib
a JAK inhibitor for alopecia areata and other autoimmune conditions
learn Pyrilutamide
highly targeted anti-androgen that might have minimal systemic effects
learn Baricitinib
JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases
learn Procyanidin
bioflavonoid found in plants with antioxidant and hair stimulating properties
Research
5 / 1000+ results
research Kinase Inhibition with BAY 43-9006 in Renal Cell Carcinoma
BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
research Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.
research Kin-Cohort Analysis of LRRK2-G2019S Penetrance in Parkinson's Disease
The LRRK2-G2019S mutation in Parkinson's disease has a lifetime penetrance of 25-35%, and finasteride may help reduce symptoms in adult male Tourette syndrome patients.
research Acquired Progressive Kinking of Hair
Acquired Progressive Kinking of Hair is likely an early sign of male pattern baldness.
research Kinetic Analysis of LY320236: Competitive Inhibitor of Type I and Non-Competitive Inhibitor of Type II Human Steroid 5α-Reductase
LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.
Community Join
5 / 1000+ resultscommunity Kintor KX -826 Pyrilutamide Adds 1 Year Phase 3 Trial For Safety
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.
community Kintor money grab, unacceptable
Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.
community Kintors interim report from 9-2-24 for everyone whos interested
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
community Kintors 1% Pyrilutamide comes in October/November
Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.
community Kintor's email response to me, regarding false advertising, and my proposal for them to develop a topical dut formulation with meaningful efficacy.
Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.